Clinical Trials Browser

Phase 2 × INDUSTRY × PM 01183 × Clear all

NCT07459634 2026-05-27

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07155174 2026-05-18

SEZanne

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05126433 2025-02-28

JAZZ EMERGE201

Phase 2 Terminated

47 enrolled 16 charts

Neoplasm Metastasis

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Phase 2 Completed

345 enrolled 34 charts 1 FDA

Other solid neoplasm

Advanced Solid Tumors

NCT01525589 2020-09-25

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Phase 2 Completed

111 enrolled 31 charts

Breast Neoplasms

NCT02451007 2019-11-19

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

Phase 2 Completed

39 enrolled 11 charts

Other solid neoplasm

Solid Tumors

NCT01951157 2019-09-24

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Completed

69 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung